Dentsply Sirona vs Blue Sail Medical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Dentsply Sirona Inc (XRAY)

Q3 202628 Jul – 6 Oct 2026

▲2▼1

Dentsply Sirona: weak sales, but profit recovery and dealer expansion

Sales still shrinking across all dental segments Second-quarter revenue fell 4.1% to $898 million, with weakness in all three dental segments, lower volumes in the Americas and Europe, soft demand for big-ticket equipment, and distributors cutting inventory. Falling sales pressure the stock even though profit beat expectations.
The core reason XRAY is under pressure is that revenue is still declining, which matters more to long-term investors than a one-quarter profit beat.
Profit recovery and cash generation, guidance kept The company returned to net income with better margins and stronger cash flow, and kept its 2026 sales target of $3.5–$3.6 billion and adjusted earnings of $1.40–$1.50 per share. It also resumed buying back shares, a sign management sees value.
Profit recovery and reaffirmed guidance are the main positive force supporting the stock despite weak sales.
Turnaround is uneven and back-loaded Management calls this a turnaround, but benefits from new sales hires and dealer additions mostly arrive in the fourth quarter and next year. Analysts questioned the timing of profit improvement, and cautious forecasts assume roughly flat revenue with only a small earnings recovery.
This explains why the stock stays volatile: promised improvement keeps getting pushed into the future, so investors must wait.
Dealer network keeps expanding into technology Dentsply expanded distribution deals with Medline Sinclair in Canada and Midwest Dental in the US, bringing its digital dentistry equipment to more customers. These are the sixth and seventh North American dealer enhancements of 2026, widening reach for higher-priced technology products.
Expanding distribution is the clearest new growth driver, aimed at reversing the equipment-demand weakness.

September 202628 Jul – 6 Oct 2026

▲2▼1

Dentsply Sirona: weak sales, but profit recovery and dealer expansion

Sales still shrinking across all dental segments Second-quarter revenue fell 4.1% to $898 million, with weakness in all three dental segments, lower volumes in the Americas and Europe, soft demand for big-ticket equipment, and distributors cutting inventory. Falling sales pressure the stock even though profit beat expectations.
The core reason XRAY is under pressure is that revenue is still declining, which matters more to long-term investors than a one-quarter profit beat.
Profit recovery and cash generation, guidance kept The company returned to net income with better margins and stronger cash flow, and kept its 2026 sales target of $3.5–$3.6 billion and adjusted earnings of $1.40–$1.50 per share. It also resumed buying back shares, a sign management sees value.
Profit recovery and reaffirmed guidance are the main positive force supporting the stock despite weak sales.
Turnaround is uneven and back-loaded Management calls this a turnaround, but benefits from new sales hires and dealer additions mostly arrive in the fourth quarter and next year. Analysts questioned the timing of profit improvement, and cautious forecasts assume roughly flat revenue with only a small earnings recovery.
This explains why the stock stays volatile: promised improvement keeps getting pushed into the future, so investors must wait.
Dealer network keeps expanding into technology Dentsply expanded distribution deals with Medline Sinclair in Canada and Midwest Dental in the US, bringing its digital dentistry equipment to more customers. These are the sixth and seventh North American dealer enhancements of 2026, widening reach for higher-priced technology products.
Expanding distribution is the clearest new growth driver, aimed at reversing the equipment-demand weakness.

Latest28 Jul – 6 Oct 2026

▲2▼1

Dentsply Sirona: weak sales, but profit recovery and dealer expansion

Sales still shrinking across all dental segments Second-quarter revenue fell 4.1% to $898 million, with weakness in all three dental segments, lower volumes in the Americas and Europe, soft demand for big-ticket equipment, and distributors cutting inventory. Falling sales pressure the stock even though profit beat expectations.
The core reason XRAY is under pressure is that revenue is still declining, which matters more to long-term investors than a one-quarter profit beat.
Profit recovery and cash generation, guidance kept The company returned to net income with better margins and stronger cash flow, and kept its 2026 sales target of $3.5–$3.6 billion and adjusted earnings of $1.40–$1.50 per share. It also resumed buying back shares, a sign management sees value.
Profit recovery and reaffirmed guidance are the main positive force supporting the stock despite weak sales.
Turnaround is uneven and back-loaded Management calls this a turnaround, but benefits from new sales hires and dealer additions mostly arrive in the fourth quarter and next year. Analysts questioned the timing of profit improvement, and cautious forecasts assume roughly flat revenue with only a small earnings recovery.
This explains why the stock stays volatile: promised improvement keeps getting pushed into the future, so investors must wait.
Dealer network keeps expanding into technology Dentsply expanded distribution deals with Medline Sinclair in Canada and Midwest Dental in the US, bringing its digital dentistry equipment to more customers. These are the sixth and seventh North American dealer enhancements of 2026, widening reach for higher-priced technology products.
Expanding distribution is the clearest new growth driver, aimed at reversing the equipment-demand weakness.

Blue Sail Medical Co Ltd (002382.CS)

Q3 202614 Jul – 25 Aug 2026

▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.
The profit turnaround is the central new fact that answers why the stock is moving.
Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.
It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.
Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.
The completed divestment is a new capital event that improves cash and focus.
Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.
It is the real counterweight explaining why profit is much lower than divisional results.

August 202614 Jul – 25 Aug 2026

▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.
The profit turnaround is the central new fact that answers why the stock is moving.
Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.
It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.
Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.
The completed divestment is a new capital event that improves cash and focus.
Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.
It is the real counterweight explaining why profit is much lower than divisional results.

Latest14 Jul – 25 Aug 2026

▲3▼1

Blue Sail swings to profit as glove prices recover and non-core unit sold

First-half profit turnaround confirmed Blue Sail expects H1 net profit of 90-110 million yuan, reversing last year's loss, and the interim report confirmed 95.7 million yuan. Both core units were profitable, with the health protection glove business swinging to a 250-300 million yuan profit on about 36% higher revenue. This is the main reason the stock has a positive story.
The profit turnaround is the central new fact that answers why the stock is moving.
Glove prices lifted the whole sector Peer Zhonghong Medical forecast profit up 23-35 times, showing the health-glove industry is recovering through higher selling prices. Blue Sail benefits from the same trend. But since May raw material costs fell and nitrile glove prices were cut, so the boost may fade later this year.
It shows the industry-wide force behind Blue Sail's profit and flags a fading tailwind.
Sale of Bikar raises cash and simplifies business Blue Sail completed the sale of its first-aid kit unit Bikar for 190 million yuan, receiving full payment. Bikar was only about 4% of revenue, so the main business is unaffected, while the cash strengthens the balance sheet and lets management focus on health protection and heart care.
The completed divestment is a new capital event that improves cash and focus.
Headquarters costs and forex losses still weigh Despite operating profits, about 150 million yuan of headquarters costs cut attributable profit, including 50 million yuan of financing repurchase interest, 24 million yuan of convertible bond interest, and foreign exchange losses. The yuan's swings hurt both Blue Sail and peers, so reported profit stays far below the divisions' combined earnings.
It is the real counterweight explaining why profit is much lower than divisional results.